Brought to you by 
Unimed, Inhale develop inhalable dronabinol
Mar 2002
Executive Summary
Solvay Pharmaceuticals' Unimed Pharmaceuticals (cardiology, men's health, HIV, and other infectious diseases) unit and Inhale Therapeutic Systems (drug delivery) will develop a metered dose inhaler of dronabinol (synthetic delta-9-tetrahydrocannabinol) to treat a variety of disorders, using Inhale's Inhance pulmonary delivery platform.
Deal Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Unimed, Inhale develop inhalable dronabinol
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice